Arbutus announces multiple abstracts highlighting imdusiran data accepted for presentation at aasld - the liver meeting® 2024

Warminster, pa., oct. 15, 2024 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), (“arbutus” or the “company”) a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis b virus (chbv) infection, today announced that clinical data with imdusiran, an rnai therapeutic, will be highlighted in four poster presentations at the american association for the study of liver diseases (aasld) – the liver meeting ® 2024, scheduled from november 15-19, 2024 in san diego, ca. this includes two late-breaking posters with imdusiran data from the im-prove i and im-prove ii phase 2a clinical trials.
ABUS Ratings Summary
ABUS Quant Ranking